Radiation Oncology

Radiation Oncology
- Sarcoma
  - VICCSAR2062
    Neoadjuvant Hypofractionated XRT in STS
    - Key Eligibility:
      1. Soft tissue sarcoma of extremity, pelvis, chest wall or trunk/abdominal wall (non-retroperitoneal location)
      2. Age >= 18 years
      3. ECOG 0-2
      4. No prior history of radiation to area to be irradiated
      5. No plans for neoadjuvant chemotherapy
      6. Localized (non-metastatic) disease
      7. Visits: Enrollment, once during treatment, once after completion of radiation, every 3-6 mos after surgery
- Thoracic
  - NSCLC
    - Localized Disease-Unresectable Stage I-IIA
    - Localized Disease-Unresectable Stage III
    - STAGE IV 1st Line
      - VICCTHOP2185
        SiCARIO for Tx of Oligometastatic NSCLC Using Biologically-Adaptive Radio Tx
        
        Key Eligibility:
        
        1. ECOG 0-2
        2. No prior systemic therapy for advanced/metastatic NSCLC (prior adjuvant chemotherapy following
        complete resection of early-stage NSCLC I-II is allowed)
        3. Participants with 5 or fewer brain metastases are eligible if intracranial sites can be treated with
        surgery and/or stereotactic radiosurgery, prior to initiation of chemo-immunotherapy
        4. Visits: SOC Chemoimmunotherapy plus radiation to oligometastatic sites (frequency of radiation
        visits determined on case by case basis)
    - Relapsed
  - SCLC
- GYN
- Breast
- CNS
- Lymphoma
  - CTCL
- Head and Neck Cancer
  - Locally Advanced HPV p1-postiive HNSCC
  - Recurrent or Metastatic
    - Resectable
      - ECOGHNEA3191
        Adj Therapy after Salvage Sx: Reirradiation/SOC Chemo vs Pembro/RT vs Pembro
        
        Key Eligibility:
        1. Recurrent oral cavity, larynx, oropharynx, hypopharynx in previously radiated field (>6 mo ago)
        2. s/p salvage resection with high-risk disease: +margins and/or +ENE
        3. Visits: daily RT; weekly visits during RT; every 6 weeks for ~11 mo; q6m phone calls for 5 years
    - Unresectable
      - No SOC remaining
  - Supportive Care
    - VICCHNP2173
      PHI/II Gabapentin+Ketamine Prev & Tx Acute & Chronic Pain Locally Adv HN CA Pts Und Prim/Adj Chemo
      - 1. Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
        2. Undergoing definitive chemoradiation
- GI
  - Rectal
    - Stage II/III
      - MSI-High/dMMR
  - Esophageal/Gastric
    - Recurrent/Metastatic
  - Anal
    - T1-2 N0 M0
- GU
  - Prostate
    - SWOGUROS1802
      Standard Systemic Therapy (SST) +/- Definitive Treatment in Metastatic Prostate Cancer
      - Key Eligibility
        1. Metastatic (conventional imaging; if only PET then bx required) prostate adenoca with an intact and resectable prostate.
        2. Between 22 - 28 weeks of SST, without PD
        3. No prior local therapy or other systemic therapy allowed
        4. Oligometastatic disease may receive metastasis directed therapy to up to four sites
        5. Visits every 3 months through 24 months, then every 6 months at M30, M36, until progression
  - Muscle-Invasive Bladder